[Elsevier] CPX-351 versus 7+3 cytarabine and daunorubicin chemotherapy in older adults with newly diagnosed high-risk or secondary acute myeloid leukaemia: 5-year results of a randomised, open-label, multicentre, phase 3 trial

paik Post time Half hour(s) ago | Show all posts |Read mode
This post will be closed automatically in 2026-06-05 07:18
Reward20points

CPX-351 versus 7+3 cytarabine and daunorubicin chemotherapy in older adults with newly diagnosed high-risk or secondary acute myeloid leukaemia: 5-year results of a randomised, open-label, multicentre, phase 3 trial


journalㄩThe Lancet Haematology

AuthorsㄩLancet, Jeffrey E; Uy, Geoffrey L; Newell, Laura F; Lin, Tara L; Ritchie, Ellen K; Stuart, Robert K

Published dateㄩ2021

DOIㄩ10.1016/s2352-3026(21)00134-4

PDF linkㄩ
https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(21)00134-4/abstract



Reply

Use magic Donate Report

All Reply0 Show all posts

Reply

You have to log in before you can reply Login | Register

Points Rules

Intermediate member
  • post

  • reply

  • points

    360


Daily Top Contributors

Return to the list